AMSTERDAM, April 16, 2021 /PRNewswire/ — LUMICKS, a leading, next-generation life science tools company that develops highly innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced the completion of a $93 million Series D preferred share financing.
The funding …
Read More